Registry for patients with myeloid neoplasms
A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Myeloid Neoplasms
This study is creating a detailed registry for people with myeloid neoplasms to gather important information that can help improve treatment and care for these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | CAR-T, immunotherapy, radiation |
| Locations | 1 site (Heidelberg, Baden-Wurttemberg) |
| Trial ID | NCT05074316 on ClinicalTrials.gov |
What this trial studies
The Myeloid Neoplasms Biology and Outcome Project (MyBOP) is designed to create a comprehensive registry for patients diagnosed with myeloid neoplasms. This observational study will collect clinical data, biological samples, socio-demographic information, and patient-reported outcomes to enhance the understanding of these conditions. By integrating long-term follow-up data, the project aims to improve evidence-based clinical management and facilitate access to personalized treatment options through clinical studies. The study also seeks to ensure quality assurance among participating centers by comparing clinical outcomes with existing published data.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a suspected or confirmed diagnosis of myeloid neoplasms.
Not a fit: Patients with severe neurological or psychiatric disorders that prevent them from providing informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this project could lead to improved clinical management and personalized treatment options for patients with myeloid neoplasms.
How similar studies have performed: Other studies focusing on registry-based approaches for myeloid neoplasms have shown promise in improving patient outcomes and understanding disease progression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or proven diagnosis of Myeloid Neoplasms according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues * Age ≥18 years * Ability to understand the nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
Where this trial is running
Heidelberg, Baden-Wurttemberg
- UHHeidelberg — Heidelberg, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Principal investigator: Richard F Schlenk, M.D. — University Hospital Heidelberg, Department of Internal Medicine V, German Cancer Research Center
- Study coordinator: Editha Gnutzmann, M.A.
- Email: editha.gnutzmann@med.uni-heidelberg.de
- Phone: +49 6221 56 36235
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.